These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25788164)

  • 1. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Trujillo A; Barnes J; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2015 Jun; 15(6):654-62. PubMed ID: 25788164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus.
    Ng S; Cowling BJ; Fang VJ; Chan KH; Ip DK; Cheng CK; Uyeki TM; Houck PM; Malik Peiris JS; Leung GM
    Clin Infect Dis; 2010 Mar; 50(5):707-14. PubMed ID: 20121573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.
    Welliver R; Monto AS; Carewicz O; Schatteman E; Hassman M; Hedrick J; Jackson HC; Huson L; Ward P; Oxford JS;
    JAMA; 2001 Feb; 285(6):748-54. PubMed ID: 11176912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial.
    Ikematsu H; Baba T; Saito MM; Kinoshita M; Miyazawa S; Hata A; Nakano S; Kitanishi Y; Hayden FG
    Influenza Other Respir Viruses; 2024 May; 18(5):e13302. PubMed ID: 38706384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
    Hirotsu N; Saisho Y; Hasegawa T
    Influenza Other Respir Viruses; 2019 Mar; 13(2):123-132. PubMed ID: 29989680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households.
    Carrat F; Duval X; Tubach F; Mosnier A; Van der Werf S; Tibi A; Blanchon T; Leport C; Flahault A; Mentré F;
    Antivir Ther; 2012; 17(6):1085-90. PubMed ID: 22910171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009.
    Goldstein E; Cowling BJ; O'Hagan JJ; Danon L; Fang VJ; Hagy A; Miller JC; Reshef D; Robins J; Biedrzycki P; Lipsitch M
    BMC Infect Dis; 2010 Jul; 10():211. PubMed ID: 20642862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
    Hayden FG; Belshe R; Villanueva C; Lanno R; Hughes C; Small I; Dutkowski R; Ward P; Carr J
    J Infect Dis; 2004 Feb; 189(3):440-9. PubMed ID: 14745701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
    Marty FM; Vidal-Puigserver J; Clark C; Gupta SK; Merino E; Garot D; Chapman MJ; Jacobs F; Rodriguez-Noriega E; Husa P; Shortino D; Watson HA; Yates PJ; Peppercorn AF
    Lancet Respir Med; 2017 Feb; 5(2):135-146. PubMed ID: 28094141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial.
    Paton NI; Lee L; Xu Y; Ooi EE; Cheung YB; Archuleta S; Wong G; Wilder-Smith A
    Lancet Infect Dis; 2011 Sep; 11(9):677-83. PubMed ID: 21550310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G; Losso MH; McClure N; Bozzolo DR; Myers C; Holley HP; Hoopes J; Lane HC; Hughes MD; Davey RT;
    Lancet Infect Dis; 2017 Dec; 17(12):1255-1265. PubMed ID: 28958678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
    Dawood FS; Jara J; Gonzalez R; Castillo JM; De León T; Estripeaut D; Luciani K; Sujey Brizuela Y; Barahona A; Cazares RA; Lawson AM; Rodriguez M; de Viana D; Franco D; Castillo M; Fry AM; Gubareva L; Tamura D; Hughes M; Gargiullo P; Clara W; Azziz-Baumgartner E; Widdowson MA
    Antiviral Res; 2016 Sep; 133():85-94. PubMed ID: 27451343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A multicenter study of efficacy and safety of oseltamivir in treatment of naturally acquired influenza].
    Li L; Cai B; Wang M; Zhu Y
    Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):838-42. PubMed ID: 16206676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial.
    Butler CC; van der Velden AW; Bongard E; Saville BR; Holmes J; Coenen S; Cook J; Francis NA; Lewis RJ; Godycki-Cwirko M; Llor C; Chlabicz S; Lionis C; Seifert B; Sundvall PD; Colliers A; Aabenhus R; Bjerrum L; Jonassen Harbin N; Lindbæk M; Glinz D; Bucher HC; Kovács B; Radzeviciene Jurgute R; Touboul Lundgren P; Little P; Murphy AW; De Sutter A; Openshaw P; de Jong MD; Connor JT; Matheeussen V; Ieven M; Goossens H; Verheij TJ
    Lancet; 2020 Jan; 395(10217):42-52. PubMed ID: 31839279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.
    Ison MG; Szakaly P; Shapira MY; Kriván G; Nist A; Dutkowski R
    Antivir Ther; 2012; 17(6):955-64. PubMed ID: 22728756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.
    Hayden FG; Gubareva LV; Monto AS; Klein TC; Elliot MJ; Hammond JM; Sharp SJ; Ossi MJ;
    N Engl J Med; 2000 Nov; 343(18):1282-9. PubMed ID: 11058672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave--New York City, April-May 2009.
    Jackson ML; France AM; Hancock K; Lu X; Veguilla V; Sun H; Liu F; Hadler J; Harcourt BH; Esposito DH; Zimmerman CM; Katz JM; Fry AM; Schrag SJ
    Clin Infect Dis; 2011 Sep; 53(5):455-62. PubMed ID: 21844028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.